Sanfilippo type A Gene therapy trial shows biopotency signals, provides Abeona Therapeutics
2 August 2016 | By Abeona Therapeutics Inc
Abeona Therapeutics provides an update on its first Sanfilippo patient and reports that early biopotency signals suggest a reduction of heparan sulfate in the urine of patients and if confirmed will suggest that intravenous administration of ABO-102 may ultimately provide both central nervous system and systemic benefits to patients...